Participation involves 7 in-person visits and will last 18 weeks.
First, potential participants will complete a screening visit, including blood and urine tests, medical history, measuring vitals, demographic information, and a questionnaire about pain.
If eligible, participants will be randomly assigned to one of four different treatment groups that will receive an investigational study drug.
The study visits will include measuring vitals, blood and urine collection, questionnaires, sensory testing, and two MRI brain scans.
In addition, participants have the option to wear an activity watch for two weeks and complete a daily sleep/activity diary.